Skip to main content
Clinical Trials/ITMCTR2100005097
ITMCTR2100005097
Not yet recruiting
未知

A Prospective and Randomized Controlled Trial of Empirical Formula of Traditinal Chinease Medicine in Treating Chronic Heart Failure

Chinese Academy of Medical Sciences Fuwai Hospital0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Chinese Academy of Medical Sciences Fuwai Hospital
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Chinese Academy of Medical Sciences Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 to 75 years;
  • 2\. Patients who meet the diagnostic criteria of Western medicine for coronary heart disease, elective patients within two weeks after DCB surgery;
  • 3\. Voluntary selection of patients who undergo coronary angiography 12 months after surgery;
  • 4\. Meet the TCM criteria for syndrome differentiation of Qi deficiency and blood stasis (total score \>\=8 points, and secondary symptoms \>\= 4 points);
  • 5\. The subjects voluntarily participated in the trial and signed the informed consent.

Exclusion Criteria

  • 1\. Heart valve disease, congenital heart disease, aortic dissection or aortic aneurysm requiring surgical or interventional treatment;
  • 2\. Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, active myocarditis, infective endocarditis, constrictive pericarditis or other pericardial diseases;
  • 3\. Patients with malignant arrhythmia and poorly controlled hypertension;
  • 4\. Cardiac synchronization therapy within 3 months; cardiac PCI, CABG and other major vascular surgery or acute coronary syndrome within 1 month;
  • 5\. Cerebrovascular events such as old stroke and transient cerebral ischemia occurred within 6 months;
  • 6\. Patients with serious primary diseases and dysfunctions of the lung, liver, kidney, hematopoietic system, immune system, etc.;
  • 7\. Subjects who participated in other drug clinical trials or interventional studies within the first four weeks of this trial;
  • 8\. Patients with serious primary diseases and dysfunctions of the lung, liver, kidney, hematopoietic system, immune system, etc.;
  • 9\. Subjects who participated in other drug clinical trials or interventional studies within the first four weeks of this trial;
  • 10\. Those who are deemed unsuitable to participate in clinical trials by the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials